About the Authors
- Hao Yin
-
Contributed equally to this work with: Hao Yin, Soo-Young Park
Affiliations Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America, Department of Surgery, Transplant Center, Shanghai Changzheng Hospital, Shanghai, People’s Republic of China
- Soo-Young Park
-
Contributed equally to this work with: Hao Yin, Soo-Young Park
Affiliation Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America
- Xiao-Jun Wang
-
Affiliations Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America, The Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, People’s Republic of China
- Ryosuke Misawa
-
Affiliations Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America, Department of Cellular Transplantation, University of Miami, Coral Gables, Florida, United States of America
- Eric J. Grossman
-
Affiliations Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America, Northwestern University Medical Center, Chicago, Illinois, United States of America
- Jing Tao
-
Affiliations Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America, The First People’s Hospital of Yunnan Province, Kunming, People’s Republic of China
- Rong Zhong
-
Affiliation Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America
- Piotr Witkowski
-
Affiliation Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America
- Graeme I. Bell
-
Affiliation Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America
- Anita S. Chong
-
* E-mail: achong@uchicago.edu
Affiliation Department of Surgery, The University of Chicago, Chicago, Illinois, United States of America
Competing Interests
This work was supported in part by grants from Takeda Pharmaceuticals. Pioglitazone and Alogliptin are Takeda Pharmaceuticals products. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Performed the experiments: HY SYP XJW RM EJG JT. Analyzed the data: HY SYP AC. Wrote the paper: AC GIB PW. Provided the data and confirmed the data analysis: HY SYP RM EJG JT. Screened and identified homozygous MIP-luc mice: RZ. Provided the MIP-luc mouse: GIB.